injectable collagen scaffold + human umbilical cord mesenchymal stem cells

This investigational cell therapy combines an injectable collagen scaffold with human umbilical cord-derived mesenchymal stem cells (HUC-MSCs) for the treatment of decompensated cirrhosis. Developed by the Chinese Academy of Sciences, the therapy is designed to be delivered directly into the liver segments via ultrasound-guided injection. The HUC-MSCs are multipotent stromal cells that possess immunomodulatory properties and the ability to secrete various cytokines and growth factors, which may promote tissue regeneration and potentially differentiate into hepatocyte-like cells. The collagen scaffold serves as a three-dimensional delivery platform that enhances the retention and survival of the transplanted cells within the cirrhotic liver. The primary biological targets are hepatic stellate cells and the underlying fibrotic processes, with the therapeutic goal of reducing liver fibrosis and improving hepatic function in patients with advanced liver disease.

Other names

Injectable Collagen Scaffold + HUC-MSCsHUC-MSCs + collagen scaffoldhuman umbilical cord-derived mesenchymal stem cells + injectable collagen scaffold